Q4 2025 Achieve Life Sciences Inc Earnings Call Transcript
Key Points
- Achieve Life Sciences Inc (ACHV) submitted a New Drug Application (NDA) for Cytisinicline, marking a significant step towards becoming the first new FDA-approved treatment for smoking cessation in 20 years.
- The company received a Commissioner's National Priority Voucher for its vaping cessation indication, providing an accelerated pathway for FDA approval.
- Clinical trials, including the ORCA-OL long-term exposure trial, demonstrated Cytisinicline's strong safety profile and patient satisfaction.
- Achieve Life Sciences Inc (ACHV) is building a scalable, data-driven commercial model using AI to enhance decision-making and customer engagement.
- The company has secured a partnership with Adair Pharma Solutions for US-based manufacturing, enhancing supply chain security and reducing risks associated with international importation.
- Achieve Life Sciences Inc (ACHV) reported a net loss of $54.7 million for the year, reflecting ongoing investments in regulatory, clinical, and commercial activities.
- There are concerns about manufacturing readiness, with observations noted during an FDA inspection of the current manufacturer, prompting a shift to US-based production.
- The timeline for the commercial launch of Cytisinicline is set for the first half of 2027, indicating a significant gap between potential NDA approval and market availability.
- The company faces challenges in raising awareness among healthcare providers due to regulatory constraints on pre-approval promotion.
- Insurance coverage at launch may face initial restrictions, requiring a ramp-up period to achieve broad payer acceptance and formulary inclusion.
Greetings, and welcome to the Achieve Life Sciences fourth quarter and full year 2025 earnings conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. (Operator Instructions)
It's now my pleasure to turn the call over to Nicole Jones, Vice President, Strategic Communications.
Nicole, please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining us today. From Achieve Life Sciences, we are joined by Rick Stewart, President and Chief Executive Officer; Dr. Mark Rubinstein, Chief Medical Officer; Jaime Xinos, Chief Commercial Officer; and Mark Oki, Chief Financial Officer. The management team will be available for Q&A following the prepared remarks.
A replay will be available later today using the information in the earnings press release or by visiting the Achieve Life Sciences website. Today's conference call will contain certain forward-looking statements, including statements regarding the goals,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
